CORTEF (hydrocortisone) by Pfizer is clinical pharmacology glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Approved for dermatomyositis, temporal arteritis, polymyositis and 14 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
CORTEF (hydrocortisone) is a naturally occurring glucocorticoid steroid administered via injection for rapid anti-inflammatory and immunosuppressive effects. It treats a broad range of conditions including autoimmune disorders (SLE, rheumatoid arthritis), allergic reactions, hematologic malignancies, and inflammatory GI disease. The drug works by modifying immune response and causing profound metabolic effects, with IV/IM formulations designed for quick onset within 1 hour and near-complete excretion within 12 hours.
Small market with stable low spending signals a niche, mature product likely managed by a lean team focused on maintenance rather than growth initiatives.
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement…
Worked on CORTEF at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
HYDROcortisone Versus Placebo for Severe HospItal-acquired Pneumonia in Intensive Care Patients: the HYDRO-SHIP Study
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
Efficacy and Safety of Topical Hydrocortisone on Signs and Symptoms of Dry Eye Associated to Meibomian Gland Dysfunction
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCORTEF generates minimal job posting activity, reflecting its small revenue base ($0.683M in Part D) and mature market position. Roles on this product are typically legacy assignments or shared across a portfolio of corticosteroids rather than dedicated brand teams.